Published in final edited form as:

Biochemistry. 2012 December 18; 51(50): 10044–10055. doi:10.1021/bi301203x.

Contributions of a disulfide bond and a reduced cysteine side chain to the intrinsic activity of the HDL receptor SR-BI

Miao Yu[‡], Thomas Y. Lau[§], Steven A. Carr[§], and Monty Krieger^{‡,*}

[‡]Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139

[§]Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142

Abstract

The high density lipoprotein (HDL) receptor, scavenger receptor class B, type I (SR-BI), binds HDL and mediates selective cholesteryl ester uptake. SR-BI's structure and mechanism are poorly understood. We used mass spectrometry to assign the two disulfide bonds in SR-BI that connect cysteines within the conserved Cys³²¹-Pro³²²-Cys³²³ (CPC) motif and connect Cys²⁸⁰ to Cys³³⁴. We used site-specific mutagenesis to evaluate the contributions of the CPC motif and the side chain of extracellular Cys³⁸⁴ to HDL binding and lipid uptake. The effects of CPC mutations on activity were context dependent. Full wild-type (WT) activity required Pro³²² and Cys³²³ only when Cys³²¹ was present. Reduced intrinsic activities were observed for CXC and CPX, but not XXC, XPX or XXX mutants (X = WT residue). Apparently, a free thiol side chain at position 321 that cannot form an intra-CPC disulfide bond with Cys³²³ is deleterious, perhaps because of aberrant disulfide bond formation. Pro³²² may stabilize an otherwise strained CPC disulfide bond, thus supporting WT activity, but this disulfide bond is not absolutely required for activity. C³⁸⁴X (X=S,T,L,Y,G,A) mutants exhibited altered activities that varied with the side chain's size: larger side chains phenocopied WT SR-BI treated with its thiosemicarbazone inhibitor BLT-1 (increased binding, decreased uptake); smaller side chains produced almost inverse effects (increased uptake:binding ratio). C³⁸⁴X mutants were BLT-1 resistant, supporting the proposal that Cys³⁸⁴'s thiol interacts with BLT-1. We discuss the implications of our findings on the functions of the extracellular loop cysteines in SR-BI and compare our results to those presented by other laboratories.

The high density lipoprotein (HDL) receptor scavenger receptor, class B, type I (SR-BI) is a cell surface receptor that plays an important role in controlling the structure and metabolism of HDL in mice and humans (1-3). Studies in mice have established the importance of SR-BI in mediating cholesterol transport, as well as gastrointestinal, endocrine, reproductive and cardiovascular physiology (reviewed in (1)), and SR-BI's role in protecting against atherosclerosis and coronary heart disease (reviewed in (1)). In humans, SR-BI influences HDL metabolism. There is considerable interest in HDL metabolism because the risk for atherosclerotic disease is inversely proportional to the levels of HDL cholesterol (4, 5).

*To whom correspondence should be addressed: 68-483, Massachusetts Institute of Technology, 31 Ames Street, Cambridge, MA 02139. Tel: 617-253-6793; FAX: 617-253-5851; Krieger@mit.edu.

Supporting Information Available. Three supplemental Figures - Figures S1, S2 and S3, supplemental Table S1, and a Supplemental Discussion may be accessed free of charge online at <http://pubs.acs.org>. Supplemental Table S1 lists the amino acid substitution mutants and the PCR primers used to generate the corresponding mutant cDNA expression vectors. Supplemental Figure S1 shows the amino acid sequence of the recombinant protein mSR-BI-t1 which was used for mass spectrometry analysis and those peptides in the unreduced protein detected by mass spectrometry. Supplemental Figure S2 illustrates the alignment of portions of the sequences of 52 SR-BI homologs. Supplemental Figure S3 shows effects of GGC or CGG mutations on ¹²⁵I-HDL binding, [³H]cholesteryl ester ([³H]CE) uptake from [³H]CE-HDL and the lipid transport efficiency (uptake-to binding ratio).

SR-BI controls HDL metabolism by mediating the transfer of cholesteryl esters in HDL particles to cells via a mechanism called selective lipid uptake (6-8). Selective lipid uptake is fundamentally different from classic receptor-mediated endocytosis via coated-pits (9). After HDL binds to the receptor, SR-BI selectively transfers the cholesteryl esters from the HDL particle into the cells. The lipid-depleted HDL subsequently dissociates from the receptor, re-enters the circulation, and the receptor is free to mediate additional rounds of selective lipid uptake. During this process, there is no requirement for cellular internalization of the SR-BI/HDL complex or degradation/hydrolysis of the HDL particles (10). The precise mechanisms underlying HDL binding and lipid uptake are not well understood.

SR-BI is a member of the large CD36 superfamily of proteins. In mammals there are three CD36 superfamily members: SR-BI, CD36 and LIMPII. CD36 is a multifunctional, cell surface protein that binds many diverse ligands, participates in fatty acid transport, and is a candidate lipid-sensor (reviewed in (11, 12)). LIMPII (Lysosomal integral membrane protein II) is located primarily in the membranes of endosomes and lysosomes. It functions as an intracellular sorting receptor for the lysosomal enzyme beta-glucocerebrosidase (13) and is involved in the pathogenesis of a subset of human enterovirus species A viruses (e.g., enterovirus 71 that causes hand, foot, and mouth disease) (14).

Members of the CD36 superfamily share a common topology with a large, glycosylated extracellular loop, and N- and C- terminal transmembrane domains, each with short cytoplasmic extensions (15). Relatively little is known about the detailed structures of these receptors or how their structures contribute to their functions. For example, only relatively recently has there been analysis of the chemical state (reduced, oxidized) and potential functional roles of the extracellular cysteines of SR-BI (16-19). There are 6 cysteine residues in the extracellular loop of SR-BI that are highly conserved in SR-BI homologs, and some of which are found in equivalent positions in CD36 and LIMPII (see Discussion). Two of them (Cys²⁵¹ and Cys³⁸⁴) are in a reduced state with free thiols, and four (Cys²⁸⁰, Cys³²¹, Cys³²³, Cys³³⁴) participate in two intramolecular disulfide bonds (16). Several studies have focused their attention on these cysteine residues in SR-BI ((16-19), see Discussion below and Supporting Information). For example, we have shown using a C³⁸⁴S mutant, that Cys³⁸⁴ is apparently important for inhibition of the receptor by the small molecule, thiosemicarbazone inhibitor BLT-1 (16, 20, 21) (apparent IC₅₀ ~50 nM) because free thiol groups can directly or indirectly interact with thiosemicarbazones and a C³⁸⁴S mutation in mouse SR-BI renders the receptor completely resistant to this inhibitor. Others have systematically mutated each extracellular loop cysteine to either Ser or Gly (17-19). Nevertheless, there remain many outstanding issues regarding these cysteines, including the precise disulfide bonding pattern and how these conserved extracellular cysteines contribute to normal receptor activities such as SR-BI-mediated HDL binding and lipid uptake.

Here, we have extended the biophysical and functional analysis of the cysteines in mouse SR-BI. We have directly determined that there is a Cys³²¹-Cys³²³ disulfide bond and infer that the second disulfide bond links Cys²⁸⁰ to Cys³³⁴. We also have used mutagenesis to focus on the roles of Cys³²¹, Cys³²³ and Cys³⁸⁴. We found that some mutations in the Cys³²¹-Pro³²²-Cys³²³ (CPC) motif, which includes an intramotif disulfide bond and is highly conserved among SR-BI homologs, can significantly reduce intrinsic receptor activity. The effects on receptor activity of any given mutation in the CPC motif can be context dependent. For example, full intrinsic receptor activity depends on a proline at position 322 when it is flanked by Cys³²¹ and Cys³²³, but not when both cysteines have been mutated. It is possible that the intervening proline in the CPC motif stabilizes the disulfide bond between Cys³²¹ and Cys³²³. Although the CPC motif in SR-BI is highly conserved, it is not critical for full, intrinsic receptor activity, as a GGG replacement of the

triplet exhibits WT receptor activity. In addition, we have shown that substitution of the Cys at position 384 by residues other than serine (C³⁸⁴X, X=T, L, Y, G and A) prevents BLT-1 inhibition, and that these C³⁸⁴X mutations can either increase or decrease SR-BI-mediated HDL binding and lipid uptake, depending on the size of the side chain.

Experimental Procedures

Materials

Lipoproteins and inhibitor—Human HDL was isolated from donors by density gradient ultracentrifugation and labeled with ¹²⁵I (¹²⁵I-HDL), or [³H]cholesteryl ester ([³H]CE, [³H]CE-HDL) as described previously (2, 22-25). BLT-1 was obtained as described (20, 21) and stored in 5 mM stock solutions in DMSO at −20 °C.

Mass spectrometric (MS) analysis of the free thiols in recombinant SR-BI-t1—

We used immunoaffinity chromatography to isolate essentially homogenously pure mSR-BI-t1 as described previously (21, 26). SR-BI-t1, a C-terminally epitope-tagged mouse SR-BI, was expressed in N-acetylglucosaminyltransferase I (GnTI)-deficient HEK293S cells (21, 27). Purified SR-BI-t1 (5 µg) was deglycosylated with 1000 U of PNGase F (Prozyme) in 20 mM MES pH 6, 15 mM NaCl and 1.5% octyl glucoside. The surfactant Rapigest (1% v/v, Waters Corp.) was added to final concentration of 0.2% to facilitate proteolytic digestion. The first step of digestion was initiated by adding sequencing grade trypsin (Promega, 1:10 enzyme to substrate ratio, 37 °C, overnight). The second step of digestion used the protease GluC (Promega) under the same conditions. Rapigest was removed by acidification with 1% Trifluoroacetic acid, precipitation and centrifugation. The samples next were desalted on C18 stagetips (28) and then the peptides were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). LC-MS/MS was performed on a Q-Exactive (Thermo, Inc.), employing a “top 12” data dependent MS/MS analysis over a 120 minute gradient. Spectra were searched against the Uniprot mouse proteome using Spectrum Mill. Initial search parameters included 30% minimum matched peak intensity, +/- 30 ppm and +/- 50 ppm tolerance on precursor and product ion masses respectively, allowing a maximum of 5 missed enzymatic cleavages. Modifications allowed included oxidized methionine, oxidized linear cysteine (for the disulfide bond mass shift) and deamidated asparagine. All data were analyzed as previously described (16).

Generation of mutant cDNAs—Site-directed mutagenesis to generate mutants was performed using the QuikChange II kit (Stratagene) on templates of either WT mouse SR-BI cDNA in the pcDNA3.1 vector or mutant SR-BI cDNAs (P³²²G and P³²²A) in the same vector. Supplemental Table S1 (Supporting Information) lists the amino acid substitution mutants and the PCR primers used to generate the corresponding PCR products. The PCR products were treated with the endonuclease DpnI and transformed into XL1-Blue supercompetent *Escherichia coli* cells by heat shock. The plasmid DNAs of selected ampicillin-resistant colonies were isolated and sequenced to confirm the presence of the mutations. The plasmid DNAs were then transformed into *E. coli* and isolated.

COS Cells and Cell Culture—COS cells were maintained and assay incubations were performed at 37 °C in a humidified 5% CO₂, 95% air incubator as previously described (16). Cellular protein levels were determined by the method of Lowry *et al* (29).

Transient expression of cDNAs in COS cells—COS cells were grown in Dulbecco's modified Eagle's medium containing 2 mM L-glutamine, 50 units/mL penicillin, and 50 µg/mL streptomycin (medium A) supplemented with 10% (vol/vol) fetal bovine serum (FBS) (medium B) and transiently transfected with WT and mutant SR-BI cDNAs embedded in

pcDNA3.1-based expression vectors. For transfections, COS cells were seeded on day 0 in the wells of 24-well dishes (50,000 cells per well) in medium B without antibiotics and grown at 37 °C overnight. On day 1 the cells were treated with 10 µg per well of the indicated expression vector DNA (WT SR-BI, mutated forms of SR-BI or the 'empty' vector (EV) pcDNA3 without an expression cassette insert as a control) using LipofectAMINE (Invitrogen) according to the manufacturer's recommendations. Antibiotics were added to the media on day 2, and then receptor activity assays were performed on day 3.

Assays

¹²⁵I-HDL binding and [³H]CE uptake from [³H]CE-HDL—On day 3 cells plated and transfected as described above were washed twice with prewarmed (37 °C) medium A plus 0.5% (wt/vol) bovine serum albumin (BSA) (medium C). ¹²⁵I-HDL binding and cellular uptake of [³H]CE from [³H]CE-HDL then were measured in medium C by adding 10 µg protein/mL of the radiolabeled HDL and incubating the cells at 37 °C for 2 h in the absence (total activity, duplicate determinations) or presence (nonspecific activity, duplicate determinations) of a 40-fold excess of unlabeled HDL (2, 6). The amounts of ¹²⁵I-HDL or [³H]CE associated with the cells were determined as previously described (2, 6, 16, 30). At least two, and usually four independent experiments were performed for all mutants. The data shown in Figures 2-5 are from representative individual experiments. The data in Supplemental Figure S3 represent averages from 3-4 independent experiments, as indicated.

Specific ¹²⁵I-HDL binding and [³H]CE uptake were calculated as the difference between total and nonspecific values. The amounts of cell-associated [³H]CE are expressed as the equivalent amount of [³H]CE-HDL protein (nanograms) to permit comparisons of the relative amounts of ¹²⁵I-HDL binding and [³H]CE uptake on the same scale (30). All errors and error bars represent standard errors of the mean. In assays using BLT-1 [37 °C, medium C plus 0.5% (vol/vol) DMSO (medium D)], cells were preincubated with or without 1 µM BLT-1 for 1 h and then incubated with radiolabeled lipoproteins as described above, all in medium D in the presence or absence of 1 µM BLT-1.

Flow cytometric analysis of SR-BI cell surface expression—Relative levels of SR-BI expressed on the cell surface were determined using the anti-SR-BI antibody KKB-1 and flow cytometry as previously described (16, 31). Briefly, COS cells were incubated with KKB-1 antibody (1/1000 dilution) at 37 °C for 1 hr in medium C containing 25 M Hepes, pH 7.4, followed by a second incubation with FITC-conjugated goat anti-rabbit IgG (AmershamBiosciences, 1/1000 dilution) at 37 °C for 1 h in the same medium, and then harvested in phosphate buffered saline (PBS) containing 2 mM EDTA. The levels of cell surface SR-BI in these unfixed cells were determined by flow cytometry using FITC fluorescence filters (31). Cell surface receptor expression was used to normalize the results for receptor activity assays (¹²⁵I-HDL binding and [³H]CE uptake) and thus permit determination of the intrinsic receptor activities independently of the surface expression level. Normalization of binding and uptake data based on surface receptor expression assumes that the mutations did not interfere with KKB-1 antibody binding.

Data Analysis—Data were analyzed using the program Prism 5 (GraphPad Software, Inc., San Diego, CA). Statistical analyses comparing either HDL binding or lipid uptake at a single substrate concentration for WT SR-BI and the individual mutants, as well as the uptake-to-binding ratio, were performed using one-way analysis of variance (ANOVA) with Tukey post-testing.

Results

Mass spectrometric determination of the disulfide bond pattern in mouse SR-BI

Previously we used mass spectrometry (MS) to show that two of the six extracellular cysteines, Cys²⁵¹ and Cys³⁸⁴, in homogeneously pure, epitope-tagged (t1) and active recombinant mouse SR-BI (SR-BI-t1) are reduced (free thiol side chains), and the other four (Cys²⁸⁰, Cys³²¹, Cys³²³, and Cys³³⁴) are involved in two intramolecular disulfide bonds, but we did not establish the bonding pattern at that time (16). To identify the precise disulfide bonding pattern we digested recombinant, purified SR-BI-t1 (see Experimental Procedures) with trypsin and GluC and analyzed the peptide products by liquid chromatography tandem mass spectrometry (LC-MS/MS). Digestion was performed after deglycosylation without prior reduction and alkylation to permit direct identification of disulfide bonds. Analysis of the unreduced receptor yielded peptides covering approximately 78% of the full-length protein sequence (Supplemental Figure S1). One of the peptides identified and characterized was F³⁰¹TAPDTLFANGSVYPPNEGFCPCR³²⁴ that contains two cysteines, Cys³²¹ and Cys³²³. The MS analysis of this peptide established that it contains an intrapeptide disulfide bond between its two cysteines (Figure 1A). Thus, there is a disulfide bond linking Cys³²¹ and Cys³²³ in mouse SR-BI (Figure 1B). We were unable to identify peptides containing Cys²⁸⁰ and Cys³³⁴ despite many attempts using a variety of digestion conditions, presumably because of incomplete digestion of the unreduced protein. Nevertheless, we infer that the second disulfide bond in SR-BI must link Cys²⁸⁰ to Cys³³⁴ (Figure 1B) because we previously established that these two cysteines participate in intramolecular disulfide bonding (16). Below we will describe additional studies of the influence of both the disulfide bond between Cys³²¹ and Cys³²³ and the nature of side chain at position 384 on SR-BI activity.

Role of Pro³²² in the CPC motif in SR-BI-mediated HDL binding and lipid uptake

Intramolecular disulfide bonds between cysteines separated by a single intervening residue, CXC, are strained and can be thermodynamically unstable (32). When proline is the intervening residue, the disulfide bond is stabilized relative to other intervening residues (32, 33). Our identification of a disulfide bond in the Cys³²¹-Pro³²²-Cys³²³ (CPC) motif raised the possibility that Pro³²² might be required to stabilize this disulfide bond. Furthermore, this CPC motif is highly conserved among members of SR-BI family of proteins (see Supplemental Figure S2), suggesting that Pro³²² may play an important role, either in stabilizing the disulfide bond or otherwise contributing to protein folding or stability of functional receptors. To investigate the role of Pro³²², we generated mutant cDNA expression vectors that encode mouse SR-BI in which the proline at position 322 in the CPC motif was converted to glycine (P³²²G) or alanine (P³²²A) (CXC, X=G or A, illustrated in Figure 2D). These vectors, as well as vectors encoding WT SR-BI and an empty vector control (EV), were transiently transfected individually into COS cells and we measured the ¹²⁵I-HDL binding and [³H]CE uptake activities (37 °C, subsaturating HDL concentration of 10 µg protein/mL). All results were corrected for the statistically significant differences in relative cell surface expression levels of the mutant receptors relative to WT, which were: WT SR-BI, 1.0; P³²²G, 0.7; and P³²²A, 0.7.

Mutation of Pro³²² to either G or A resulted in significant reductions (~60%) in both ¹²⁵I-HDL binding (Figure 2, panel A) and [³H]CE uptake from [³H]CE-HDL (Figure 2, panel B) compared to WT SR-BI. However the ratio of uptake to binding - the efficiency of lipid transport - mediated by these mutants did not differ from that of WT SR-BI (Figure 2C). These results suggest that the conserved Pro³²² in the context of the CPC motif significantly contributes to SR-BI-mediated receptor activities, primarily at the level of intrinsic HDL binding.

Role of Cys³²¹ and Cys³²³ in the CPC motif in SR-BI-mediated HDL binding and lipid uptake activities

Although the results from the Pro³²² mutants are consistent with a mechanism by which Pro³²² influences receptor activity by stabilizing the CPC disulfide bond in mouse SR-BI, a study by Guo *et al* (18) suggested this might not be the case. Guo *et al* reported that a C³²¹G mutation (GPC) does not alter receptor activity (HDL binding and lipid uptake) in human SR-BI, even though such a mutation would disrupt what we now know to be the intra-CPC motif's disulfide bond. They also reported that a C³²³G mutation (CPG) dramatically reduces both HDL binding and lipid uptake (18). Others have also reported analyses of C³²¹S and C³²³S mutants in mouse and rat SR-BI ((17, 19), see Discussion and Supporting Information). Using mouse SR-BI, we repeated and extended this work by substituting either Gly or Ser for Cys at these two positions in the CPC motif (illustrated in Figure 3D, XPC or CPX, where X=G or S) and measuring the receptors' activities in transiently transfected COS cells (37 °C, 10 µg of HDL protein/mL). All results were corrected for the statistically significant differences in relative cell surface expression levels of the mutant receptors relative to WT, which were: WT SR-BI, 1.0; C³²¹G, 0.8; C³²¹S, 0.7; C³²³G, 0.7; and C³²³S, 0.6.

Single amino acid substitutions at Cys³²³ (CPX, X=G or S) resulted in significant (~50%) reductions in both ¹²⁵I-HDL binding (Figure 3A) and [³H]CE uptake (Figure 3B), yet did not alter the overall efficiency of lipid transport (ratio of uptake to binding, Figure 3C). Others have also reported decreased activity in Cys³²³ (CPX, X=G or S) mutants, although the extent of decrease varied somewhat in different studies (17-19). In addition we found that mutations at Cys³²¹ (XPC) had either no significant effect on HDL binding and lipid uptake (X=G) or resulted in only a slight, although statistically significant, decrease (~20%) in HDL binding, but not in lipid uptake (X=S, Figure 3A and B). The XPC mutations did not alter the overall efficiency of lipid transport (Figure 3C). The essentially (80%-100%) WT levels of activities of the C³²¹X mutants (XPC) suggest that our results with mouse SR-BI are consistent with those reported by Guo *et al* (18) for human SR-BI and confirm that the disulfide bond in the CPC motif is not necessary for essentially normal receptor-mediated HDL binding and lipid uptake activities. However, others have reported different results for the effects of C³²¹S mutation on SR-BI from mouse (17) or rat (19) (see Discussion and Supporting Information for details).

Consequences of disrupting native disulfide formation at Cys³²¹ on SR-BI-mediated HDL binding and lipid uptake

We were intrigued by the similarities in the extents (40-50%) to which HDL binding activities were reduced in the Pro³²² (CXC, X=A, G) and Cys³²³ (CPX, X=G, S) mutants. In both sets of mutants the side chain of Cys³²¹ either could not form (CPX, X=C) or, because of steric and thermodynamic considerations (CXC, X=P), was not expected to form a stable disulfide bond with the side chain at position 323. In these mutants, the sulfhydryl group of Cys³²¹ might either be a free thiol or form a non-native (inappropriate) disulfide bond with a different cysteine either in the same SR-BI molecule (e.g., the free sulfhydryls at Cys²⁵¹ or Cys³⁸⁴) or in some other protein. This raised the possibility that the inability of Cys³²¹'s thiol group to form a disulfide bond with Cys³²³ was responsible for the similarity in reduction of HDL binding activities for these mutants. To test this possibility, we generated an expression vector encoding a Gly³²¹Pro³²²Gly³²³ (GPG) double mutant (illustrated in Figure 4D) that could not form the disulfide bond nor have a free thiol or inappropriate disulfide bond at position 321. We expressed the mutant in transiently transfected COS cells and determined its HDL binding and lipid uptake activities as described above. All results were corrected for differences in relative cell surface expression levels of the receptors, which were not statistically significant: WT SR-BI, 1.0; GPG, 0.9. Figure 4, panels A-C,

shows that the GPG mutant (second bars from the left) exhibited normal HDL binding and lipid uptake activities (compare to WT, leftmost bars). Thus, Cys is not required at either position 321 or 323 for WT levels of receptor-mediated HDL binding and lipid uptake activities. The reduced HDL binding activities in CXC and CPX mutants was likely a consequence of either a free thiol or inappropriate disulfide bonding at Cys³²¹.

The essentially normal activity of the double GPG mutant permitted us to further assess the role of the conserved Pro³²² independently of any effects that the adjacent Cys residues or the Cys³²¹-Cys³²³ disulfide bond might have on it. We generated and analyzed in transfected COS cells the activities of triple, GXG (X=G, A) mutants (illustrated in Figure 4D). All results were corrected for relative cell surface expression levels of the receptors, which were not statistically significant and were: WT SR-BI, 1.0; GXG (X=G, A), 1.0. Figure 4, panels A-C, shows that both GXG triple mutants exhibited HDL binding and lipid uptake activities that were not significantly different than those of the WT SR-BI or the GPG double mutant. Thus, essentially normal receptor activity does not require a Pro at position 322 when both cysteines are replaced by glycines at positions 321 and 323 (no disulfide bond). These results suggest that the reduction in HDL binding activity in CXC mutants when X = P may be due to the destabilization of the disulfide bond and consequent inappropriate interactions of the side chains of Cys³²¹ and/or Cys³²³ (free thiols and/or non-native disulfide bonding). There appears to be no intrinsic dependence on the proline at position 322 for the receptor's functional folding, surface expression and activity.

To complete the mutational analysis of the CPC motif we generated and analyzed the activities of two additional mutants that are single residue modifications of the fully active G³²¹G³²²G³²³ mutant: GGC and CGG (Supplemental Figure 3). The binding and lipid uptake activities of the GGC mutant (Supplemental Figure 3A-C) were not significantly different than those of the WT receptor, whereas those for the CGG mutant were significantly less (~20%) than those of the WT receptor. The reduction in uptake activity by the CGG mutant was significantly less than that by the CPG mutant (~50%, Figure 3 and Supplemental Figure S3, panels B). Perhaps steric or entropic constraints imposed by Pro³²², but not Gly³²², in CXG mutants force the side chain of Cys³²¹, and thus the receptor's extracellular domain, into a less productive conformation when a Cys³²¹-Cys³²³ disulfide cannot form. These findings confirm that when Cys³²¹ cannot form a disulfide bond with Cys³²³, the Cys³²¹ reduces intrinsic receptor activity.

Effect of the amino acid identity at position 384 on SR-BI-mediated HDL binding and lipid uptake activities and sensitivity to BLT-1 inhibition

We previously reported that a C³⁸⁴S mutation significantly altered the lipid uptake activity of mouse SR-BI (16). To determine if variation in the size of the amino acid side chain at position 384 affects SR-BI-mediated HDL binding and lipid uptake activities, we generated multiple mutant cDNA expression vectors that encode mouse SR-BI in which Cys³⁸⁴ was substituted by amino acids with larger side chains - threonine (C³⁸⁴T), leucine (C³⁸⁴L), and tyrosine (C³⁸⁴Y), smaller side chains - glycine (C³⁸⁴G) and alanine (C³⁸⁴A), or a similarly sized side chain - serine (C³⁸⁴S). These vectors, as well as vectors encoding WT SR-BI and an empty vector control (EV), were transiently transfected individually into COS cells. Receptor activities - ¹²⁵I-HDL binding and [³H]CE uptake from [³H]CE-HDL - of each mutant in these cells were measured at 37 °C at a subsaturating concentration of HDL (10 µg protein/mL). All results were corrected for differences in relative cell surface expression levels of the receptors (determined by flow cytometry, see Experimental Procedures). The relative surface expression levels, which were not statistically significant from the WT receptor, were: WT SR-BI, 1.0; C³⁸⁴S, 0.9; C³⁸⁴T, 1.0; C³⁸⁴L, 1.0; C³⁸⁴Y, 1.0; C³⁸⁴G, 0.9; and C³⁸⁴A, 0.9.

Figure 5A shows that compared to WT SR-BI, the C³⁸⁴T, C³⁸⁴L and C³⁸⁴Y variants with the larger side chains exhibited significant, ~150-200% increases in HDL binding, while binding to the C³⁸⁴G and C³⁸⁴A variants with the smaller side chains was reduced by ~35% (one-way ANOVA analysis with Tukey post-testing). As we reported previously (16), ¹²⁵I-HDL binding to C³⁸⁴S did not differ from that to WT SR-BI. There also were significant reductions relative to the WT control in [³H]CE uptake from [³H]CE-HDL mediated by the C³⁸⁴T, C³⁸⁴L or C³⁸⁴Y variants (larger side chains), but not the C³⁸⁴G or C³⁸⁴A mutants with smaller side chains (Figure 5B). To compare the lipid transport efficiencies of WT SR-BI and its variants (amount of lipid transport normalized for surface ¹²⁵I-HDL binding), we calculated the ratio of [³H]CE uptake to ¹²⁵I-HDL binding (Figure 5C). The efficiency of lipid transport mediated by mutants in which Cys³⁸⁴ was replaced by residues with larger side chains (C³⁸⁴T, C³⁸⁴L and C³⁸⁴Y) was significantly reduced, whereas it was significantly increased for those (C³⁸⁴G or C³⁸⁴A) whose side chains are substantially smaller. As previously reported (16), the lipid transport efficiency of C³⁸⁴S, was significantly lower than that of the WT SR-BI, but exhibited no alteration in HDL binding. The relationship of these findings to those reported by others (17-19) for mutations at Cys³⁸⁴ will be considered in Discussion and Supporting Information.

The apparent increase in HDL binding and reduction in lipid uptake in mutants at position 384 whose side chains are larger than that of cysteine (T, L, Y) closely resemble the effects of the small molecule inhibitor BLT-1 (apparent IC₅₀ ~50 nM, Figure 5D) on WT SR-BI – increased binding at subsaturating HDL concentrations accompanied by decreased lipid uptake (20). Based on structure activity relationship analysis, which showed the thiosemicarbazone moiety in BLT-1 was important for its activity (21), as well as loss of BLT-1 sensitivity of the C³⁸⁴S mutant, we suggested that a free sulfhydryl side chain at position 384 is required for BLT-1 sensitivity (16). Figure 5E and F shows that all of the other C³⁸⁴X mutants (X=T, L, Y, G and A) expressed transiently in COS cells also are resistant to BLT-1 (1 μM) with no BLT-1-induced significant change in HDL binding (panel E) or lipid uptake (panel F). These results support the proposal that in WT SR-BI the free sulfhydryl at position 384 may directly or indirectly interact with BLT-1 and they raise the possibility that larger side chains at position 384 might mimic the effects of BLT-1 by occupying some of the space into which BLT-1 binds, although other explanations are possible.

Discussion

Relatively little is known about the detailed structure of SR-BI or how its structure contributes to its functions. For example, only relatively recently has there been analysis of the chemical state (reduced, oxidized) and potential functional roles of the extracellular cysteines of SR-BI (16-19). In the current study, we have determined the disulfide bonding pattern in recombinant mouse (m)SR-BI purified from mammalian cells overexpressing the protein using mass spectrometry. We previously showed that purified mSR-BI's six extracellular cysteines form two disulfide bonds involving Cys²⁸⁰, Cys³²¹, Cys³²² and Cys³³⁴, and that the side chains of Cys²⁵¹ and Cys³⁸⁴ are in the reduced, thiol state (16). Independently, Papale *et al* (17) suggested based on mutagenesis studies that there might be two disulfide bonds linking cysteines at position 280, 321, 323 and 334. Subsequently, Hu *et al* (19) also suggested that cysteines 280, 321, 323 and 334 might be involved in disulfide bond formation based on the reduced cell surface levels of expression of rat (r)SR-BI with serine mutations at these positions. We have now established directly that there is a disulfide bond linking Cys³²¹ and Cys³²³, and therefore that the second disulfide bond links Cys²⁸⁰ and Cys³³⁴ (Figure 1B and 7). Papale *et al* (17) and Metcalfe *et al* (34) have reported that the side chain of SR-BI's Cys³⁸⁴ in intact cells is resistant to modification by sulfhydryl reagents. This resistance might have been due to its participation in a disulfide bond (17,

34). Alternatively, direct MS analysis suggests that the side chain of Cys³⁸⁴ is a free sulfhydryl group (16) that may be buried (see below) and thus inaccessible to these reagents unless the native structure is perturbed (34). It is noteworthy that SR-BI's disulfide pattern (Figure 6, left panel) differs considerably from that reported by Rasmussen *et al* (35) for SR-BI's homolog bovine CD36 (Figure 6, middle panel), the first and only other report of the disulfide pattern in a member of the CD36 superfamily of proteins. In SR-BI and CD36, five of the six extracellular loop cysteines are in precisely or nearly equivalent positions in the aligned (BLAST (36)) primary sequences (Figure 6): 251/243 (SR-BI/CD36), 280/272, 321/311, 323/313, and 334/333. There is no cysteine in CD36's sequence that is near SR-BI's Cys³⁸⁴. Because of the relatively poor sequence similarity in the region containing cysteines 321-323-334 in SR-BI and 311-313-322-333 in CD36, as well as a gap in that region in CD36 relative to SR-BI, the relative alignment of cysteines in this region is ambiguous and that shown in Figure 6 is slightly modified relative to that produced by BLAST in order to align the two CXC motifs in SR-BI and CD36.

The six extracellular loop cysteines in bovine CD36 are reported to form three disulfide bonds (Figure 6): Cys²⁴³-Cys³¹¹, Cys²⁷²-Cys³³³ and Cys³¹³-Cys³²² (35). The disulfide of CD36 linking Cys²⁷²-Cys³³³ and that of SR-BI linking Cys²⁸⁰-Cys³³⁴ are in equivalent positions in the sequences based on BLAST and COBALT sequence alignments (36, 37), and thus are presumably in structurally equivalent positions (denoted by dotted lines in Figure 6). The other mammalian CD36 family member, LIMPII, has only five extracellular loop cysteines (Figure 6, right), three of which have clear equivalents in SR-BI: 251/224 (SR-BI/LIMPII); 280/274 and 334/330, respectively. The other two cysteines in LIMPII, 312 and 318, are close to, but due to sequence gaps difficult to match unequivocally with, SR-BI's Cys³²¹, Cys³²³ and Cys³³⁴. At least one of the cysteine side chains in LIMPII must either be a free thiol or participate in intermolecular disulfide bonding. It seems possible that there may be a disulfide bond in LIMPII linking Cys²⁷⁴ to Cys³³⁰ that would be equivalent to the apparently common disulfide bond in SR-BI (Cys²⁸⁰-Cys³³⁴) and CD36 (Cys²⁷²-Cys³³³). There is no CXC motif in LIMPII, but there is one in CD36, C³¹¹F³¹²C³¹³, that seems likely to be in a position analogous to that of the C³²¹P³²²C³²³ in SR-BI. However, as might be expected because of the intervening phenylalanine, these two cysteines in CD36 (C³¹¹F³¹²C³¹³) apparently are not disulfide bonded to each other as they are in SR-BI ((35) and see below).

We (16) and others (17-19) previously have studied the influence of cysteines on SR-BI's activities by mutating its cysteines individually or in groups to either Ser or Gly and then measuring the cell surface expression and receptor activities of the mutants expressed from transfected cDNAs in cultured cells. Four different groups have reported results using either mouse (m), rat (r) or human (h) SR-BI and a variety of expression vectors and assays (16-19). Papale *et al* (17), Guo *et al* (18) and Hu *et al* (19) independently have systematically mutated each of the six extracellular loop cysteines and studied their effects on HDL binding and lipid uptake. All of the published reports considered cell surface expression as well as absolute levels of receptor activity (binding, lipid uptake). While some of the results for some of the mutations in these independent reports and the current study are similar (e.g., no effect of a C³²¹G mutation on receptor activity reported by Guo *et al* (18) and in this study), no two of these reports are in full accord. Some examples of the similarities and differences are described in the Supplemental Discussion (see Supporting Information). Here we have repeated and in some cases extended previously reported analyses of mutations of cysteines at positions 384, 321 and 323, exclusively using mSR-BI, a common expression vector and the same methods for transiently transfecting expression vectors into COS cells and measuring receptor activities, with explicit normalization for cell surface expression differences.

Cys³²¹Pro³²²Cys³²³

Sequence analysis (BLAST, COBALT) of CD36 superfamily members suggests that SR-BI homologs are the only members of the superfamily to have Cys³²¹-Pro³²²-Cys³²³ (CPC) triplet motif (unpublished and see sequences of SR-BI homologs in Supplemental Figure S2), which we have shown contains an intramotif disulfide bond in mSR-BI. Those SR-BI homologs identified using BLAST (includes, mammals (primates, rodents, marsupial), birds, amphibian, reptile) all have a Cys at position 384, except fish (5 of 5 have V³⁸⁴, 4 of 5 have Cys²⁵¹ and all have Cys²⁸⁰, Cys³²¹, Cys³²³ and Cys³³⁴). Although invertebrates have many CD36 superfamily members, we have not identified equivalent CPC-containing SR-BI homologs in invertebrates. CX_nC (n = 1) motifs can mediate oxidation sensitive metal binding (38-40) and CPC and CXXC motifs can mimic the activity of thioredoxin and protein disulfide isomerase (PDI) (thiol-disulfide exchange) (33, 41, 42). Thiol-disulfide exchange has been proposed to be a key trigger of envelope-protein-induced fusion of some viral envelopes and their target cell plasma membranes, and the fusion proteins of some viruses contain the CXXC motif (43-45). One proposed mechanism by which SR-BI may mediate selective lipid uptake is via hemifusion (31, 46, 47) of the phospholipid/protein monolayer shell of HDL with the plasma membrane, a process that would be somewhat similar to at least the first steps of viral membrane fusion. An additional potential role of Cys³²³, first described by Li and colleagues (18, 48, 49), is that Cys³²³ in the CPC motif is also part of another short, conserved sequence in SR-BI, ³²³CXXS³²⁶, that belong to the CXXC/S redox family motif. Guo *et al* have suggested that the site of HDL binding to SR-BI may lie close to the CXXS (and thus the CPC) motif (18).

We examined the potential contributions of each of the residues in the CPC motif to SR-BI activity by generating single substitution mutations at each position followed by testing the HDL binding and lipid uptake activities of the variants. Intramolecular disulfide bonds between cysteines separated by a single intervening residue (CXC) can be thermodynamically unstable due to entropic considerations (32). When proline is the intervening residue, such as the CPC in SR-BI, the disulfide bond is stabilized relative to other intervening residues (32, 33). Full WT activity of SR-BI required Pro³²² and Cys³²³ only when Cys³²¹ was present – there were reduced intrinsic activities of CXC and CPX mutant, but essentially wild-type activities of XXC, XPX or XXX mutants (X = WT residue, e.g., GGG mutant). Indeed, in all independent reports to date (17-19 and this study), CPX mutants (X³²³ C) exhibited significantly reduced receptor activities (e.g., ~50% of WT). WT levels of intrinsic receptor HDL binding and lipid uptake activities do not require absolutely 1) a disulfide bond linking positions 321 and 323, 2) cysteines at either of these two positions, or 3) a proline at position 322. Nevertheless, a free thiol side chain at position 321 that cannot form disulfide bond with Cys³²³ is deleterious, perhaps because of aberrant intra- or intermolecular disulfide bond formation with other cysteines (e.g., the free sulfhydryls at Cys²⁵¹ or Cys³⁸⁴ in SR-BI). Others (17, 19) have also noted that mutations disrupting potential disulfide bonds in SR-BI could result in formation of aberrant disulfide bonds that could interfere with surface expression, HDL binding and/or lipid uptake. It appears likely that the conserved Pro³²² stabilizes an otherwise strained CPC disulfide bond, thus supporting full SR-BI HDL binding and lipid uptake activities. Why is the CPC motif with an intramotif disulfide bond so highly conserved among apparent SR-BI homologs (Supplemental Figure S2), but not other members of the CD36 superfamily, yet it can be replaced by a GGG triplet without altering HDL binding and lipid uptake? Perhaps the ³²¹CPC³²³ and/or ³²³CXXS³²⁶ motifs play critical roles in SR-BI activities (e.g., see (48, 49)) that are independent of HDL binding and lipid uptake activities examined in this study. In this regard it is noteworthy that in addition to mediating the transport of lipid between cells and lipoproteins, SR-BI can serve as a signaling receptor to activate

intracellular signaling cascades (50-52) and as a receptor that mediates hepatitis C virus entry into hepatocytes (53-61).

Cys³⁸⁴

We previously reported that for mSR-BI a C³⁸⁴S mutation resulted in a receptor that was completely resistant to the inhibitor BLT-1 (16). BLT-1's inhibitory activity depends on its thiosemicarbazone group (21) which we suggested is likely to interact directly or indirectly with Cys³⁸⁴ (16). Treatment of WT SR-BI with BLT-1 irreversibly inhibits lipid uptake while increasing HDL binding affinity (20). Thus, the efficiency of lipid uptake in WT SR-BI (ratio of uptake-to-binding) is reduced by BLT-1. We also observed in the mSR-BI C³⁸⁴S mutant a significant (60%) decrease in lipid uptake activity without alteration in HDL binding (16). However, others have reported contemporaneously or soon thereafter that C³⁸⁴S substitution in mSR-BI (17) or rSR-BI (19), or C³⁸⁴G substitution in hSR-BI (18) had little or no significant effects on HDL binding and lipid uptake activities. We revisited the role of Cys³⁸⁴ by analyzing HDL binding and lipid uptake as well as the inhibitory activity of BLT-1 on a series of C³⁸⁴X mutants, where the side chains of the replacement residues were either larger than (X=T, L, Y), smaller than (X=G, A) or about the same size as (X=S) that of cysteine.

We found that all of the substitutions at Cys³⁸⁴ resulted in complete resistance to inhibition by BLT-1, confirming our earlier results with C³⁸⁴S (16). We also found that the influence of these Cys³⁸⁴ substitutions on receptor activity varied depending on the replacement's side chain. The efficiency of lipid transport was significantly reduced when Cys³⁸⁴ was replaced by residues with larger side chains due to increased binding and decreased uptake - a result similar to that seen in WT SR-BI treated with BLT-1 (20). In contrast, efficiency of lipid transport was significantly increased for those residues with substantially smaller side chains due to reduced binding but essentially normal uptake. One potential explanation of these findings is that in mutants with larger side chains at position 384, those side chains might occupy the same binding site as does BLT-1 or otherwise distort the native conformation of the receptor in a fashion similar to BLT-1, and thus mimic the effect of BLT-1. It is possible that the free sulfhydryl at Cys³⁸⁴ in WT SR-BI directly or indirectly (e.g., via ligating to an intermediary metal ion) interacts with BLT-1(16), with the bulk of the bound BLT-1 molecule occupying a cavity immediately adjacent to Cys³⁸⁴'s side chain. In contrast, the smaller side chains in the Cys³⁸⁴X (X=G or A) mutants apparently have an opposite influence (increased efficiency of lipid transport).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank M. Penman for technical assistance and Deborah Fass, Daisy Sahoo, Thomas Nieland and Andrew Nager for helpful discussions and/or suggestions.

Funding sources: This work was supported by research grants from the NIH to MK (HL052212 and HL066105), MY was supported, in part, by an NIH graduate student training grant (#5-T32-GM007287), and TL was supported by grants from the Womens Cancer Research Fund and the Komen Foundation to SAC.

Abbreviations

HDL	high density lipoprotein
SR-BI	scavenger receptor class B type I

CE	cholesteryl ester
Cys or C	cysteine
Gly or G	glycine
Pro or P	proline
Ser or S	serine
LC-MS/MS	liquid chromatography tandem mass spectrometry
WT	wild-type

References

1. Rigotti A, Miettinen HE, Krieger M. The Role of the High-Density Lipoprotein Receptor SR-BI in the Lipid Metabolism of Endocrine and Other Tissues. *Endocr Rev.* 2003; 24:357–387. [PubMed: 12788804]
2. Nieland TJF, Xu S, Penman M, Krieger M. Negatively Cooperative Binding of High-Density Lipoprotein to the HDL Receptor SR-BI. *Biochemistry.* 2011; 50:1818–1830. [PubMed: 21254782]
3. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li XH, Guo XQ, Li MY, Cho YS, Go MJ, Kim YJ, Lee JY, Park T, Kim K, Sim X, Ong RTH, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Zhao JH, Yuan X, Luan JA, Lamina C, Ziegler A, Zhang W, Zee RYL, Wright AF, Witteman JCM, Wilson JF, Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJG, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruukonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx B, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O'Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PKE, Lucas G, Luben R, Loos RJJ, Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, Konig IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Janssens A, Ingelsson E, Igi W, Hovingh GK, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllenstein U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Doering A, Dominiczak AF, Demissie S, Deloukas P, de Geus EJC, de Faire U, Crawford G, Collins FS, Chen YDI, Caulfield MJ, Campbell H, Burt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor HA, Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JJP, Schadt EE, Rotter JJ, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature.* 466:707–713. [PubMed: 20686565]
4. Gordon T, Castelli W, Hjortland M, Kannel W, Dawber T. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. *Am J Med.* 1977; 62:707–714. [PubMed: 193398]
5. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. *Lancet.* 1975; 305:16–19. [PubMed: 46338]
6. Acton S, Rigotti A, Landschulz KT, Xu SZ, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. *Science.* 1996; 271:518–520. [PubMed: 8560269]

7. Glass C, Pittman RC, Weinstein DB, Steinberg D. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. *Proc. Natl. Acad. Sci. U. S. A.* 1983; 80:5435–5439. [PubMed: 6412229]
8. Stein Y, Dabach Y, Hollander G, Halperin G, Stein O. Metabolism of HDL-cholesteryl ester in the rat, studied with a nonhydrolyzable analog, cholesteryl linoleyl ether. *Biochimica et Biophysica Acta.* 1983; 752:98–105. [PubMed: 6849969]
9. Goldstein JL, Brown MS. The LDL Receptor. *Arterioscler. Thromb. Vasc. Biol.* 2009; 29:431–438. [PubMed: 19299327]
10. Nieland TJF, Ehrlich M, Krieger M, Kirchhausen T. Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids.* 2005; 1734:44–51.
11. Silverstein RL, Febbraio M. CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior. *Sci. Signal.* 2. 2009
12. Chevrot M, Martin C, Passilly-Degrace P, Besnard P. Role of CD36 in oral and postoral sensing of lipids. *Handbook of experimental pharmacology.* 2012:295–307. [PubMed: 22249820]
13. Reczek D, Schwake M, Schroder J, Hughes H, Blanz J, Jin XY, Brondyk W, Van Patten S, Edmunds T, Saftig P. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-Glucocerebrosidase. *Cell.* 2007; 131:770–783. [PubMed: 18022370]
14. Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, Nishimura H, Sanjoh K, Katsushima N, Itagaki T, Nagai Y, Fujii K, Koike S. Human SCARB2-Dependent Infection by Coxsackievirus A7, A14, and A16 and Enterovirus 71. *J. Virol.* 2012; 86:5686–5696. [PubMed: 22438546]
15. Greenwalt DE, Lipsky RH, Ockenhouse CF, Ikeda H, Tandon NN, Jamieson GA. Membrane glycoprotein-CD36- a review of its roles in adherence, signal transduction, and transfusion medicine. *Blood.* 1992; 80:1105–1115. [PubMed: 1381234]
16. Yu M, Romer KA, Nieland TJF, Xu SZ, Saenz-Vash V, Penman M, Yesilaltay A, Carr SA, Krieger M. Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity. *Proc. Natl. Acad. Sci. U. S. A.* 2011; 108:12243–12248. [PubMed: 21746906]
17. Papale GA, Hanson PJ, Sahoo D. Extracellular Disulfide Bonds Support Scavenger Receptor Class B Type I-Mediated Cholesterol Transport. *Biochemistry.* 2011; 50:6245–6254. [PubMed: 21675794]
18. Guo L, Chen M, Song Z, Daugherty A, Li X. C323 of SR-BI is required for SR-BI-mediated HDL binding and cholesteryl ester uptake. *J- Lipid Res.* 2011
19. Hu J, Zhang ZH, Shen WJ, Nomoto A, Azhar S. Differential Roles of Cysteine Residues in the Cellular Trafficking, Dimerization, and Function of the High-Density Lipoprotein Receptor, SR-BI. *Biochemistry.* 2011; 50:10860–10875. [PubMed: 22097902]
20. Nieland TJF, Penman M, Dori L, Krieger M, Kirchhausen T. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. *Proc. Natl. Acad. Sci. U. S. A.* 2002; 99:15422–15427. [PubMed: 12438696]
21. Nieland TJF, Shaw JT, Jaipuri FA, Duffner JL, Koehler AN, Banakos S, Zannis VI, Kirchhausen T, Krieger M. Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity. *Biochemistry.* 2008; 47:460–472. [PubMed: 18067275]
22. Chung BH, Wilkinson T, Geer JC, Segrest JP. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. *J Lipid Res.* 1980; 21:284–291. [PubMed: 7381323]
23. Patsch JR, Patsch W. Zonal ultracentrifugation. *Methods Enzymol.* 1986; 129:3–26. [PubMed: 3724543]
24. Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. *Methods Enzymol.* 1983; 98:241–260. [PubMed: 6321901]
25. Gwynne JT, Mahaffee DD. Rat adrenal uptake and metabolism of high density lipoprotein cholesteryl ester. *J. Biol. Chem.* 1989; 264:8141–8150. [PubMed: 2542267]

26. Liu B, Krieger M. Highly purified scavenger receptor class B type I reconstituted into phosphatidylcholine/cholesterol liposomes mediates high affinity high density lipoprotein binding and selective lipid uptake. *J. Biol. Chem.* 2002; 277:34125–34135. [PubMed: 12110672]
27. Reeves PJ, Kim JM, Khorana HG. Structure and function in rhodopsin: A tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants. *Proc. Natl. Acad. Sci. U. S. A.* 2002; 99:13413–13418. [PubMed: 12370422]
28. Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. *Nat. Protocols.* 2007; 2:1896–1906.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem.* 1951; 193:265–275. [PubMed: 14907713]
30. Pittman RC, Knecht TP, Rosenbaum MS, Taylor CA Jr. A nonendocytotic mechanism for the selective uptake of high density lipoprotein-associated cholesterol esters. *J Biol Chem.* 1987; 262:2443–2450. [PubMed: 2434485]
31. Gu X, Kozarsky K, Krieger M. Scavenger receptor class B, type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor. *J Biol Chem.* 2000; 275:29993–30001. [PubMed: 11001950]
32. Zhang RM, Snyder GH. Dependence of formation of small disulfide loops in 2-cysteine peptides on the number and types of intervening amino-acids. *J. Biol. Chem.* 1989; 264:18472–18479. [PubMed: 2808384]
33. Woycechowsky KJ, Raines RT. The CXC motif: A functional mimic of protein disulfide isomerase. *Biochemistry.* 2003; 42:5387–5394. [PubMed: 12731880]
34. Metcalfe C, Cresswell P, Ciaccia L, Thomas B, Barclay AN. Labile disulfide bonds are common at the leucocyte cell surface. *Open Biol* 1. 2011
35. Rasmussen JT, Berglund L, Rasmussen MS, Petersen TE. Assignment of disulfide bridges in bovine CD36. *Eur. J. Biochem.* 1998; 257:488–494. [PubMed: 9826197]
36. Altschul S, Gish W, Miller W, Myers E, Lipman D. Basic local alignment search tool. *J Mol Biol.* 1990; 215:403–410. [PubMed: 2231712]
37. Papadopoulos J, Agarwala R. COBAL: constraint-based alignment tool for multiple protein sequences. *Bioinformatics.* 2007; 23:1073–1079. [PubMed: 17332019]
38. Cun SJ, Sun HZ. A zinc-binding site by negative selection induces metalloprotein susceptibility in an essential chaperonin. *Proc. Natl. Acad. Sci. U. S. A.* 2009; 107:4943–4948. [PubMed: 20194796]
39. Zhou YB, Tzeng WP, Ye YM, Huang Y, Li SY, Chen YY, Frey TK, Yang JJ. A cysteine-rich metal-binding domain from rubella virus non-structural protein is essential for viral protease activity and virus replication. *Biochem. J.* 2009; 417:477–483. [PubMed: 18795894]
40. Potocki S, Rowinska-Zyrek M, Valensin D, Krzywoszynska K, Witkowska D, Luczkowski M, Kozlowski H. Metal Binding Ability of Cysteine-Rich Peptide Domain of ZIP13 Zn(2+) Ions Transporter. *Inorganic Chemistry.* 2011; 50:6135–6145. [PubMed: 21630642]
41. Bachnoff N, Trus M, Atlas D. Alleviation of oxidative stress by potent and selective thioredoxin-mimetic peptides. *Free Radic. Biol. Med.* 2011; 50:1355–1367. [PubMed: 21377525]
42. Derewenda U, Boczek T, Gorres KL, Yu M, Hung LW, Cooper D, Joachimiak A, Raines RT, Derewenda ZS. Structure and Function of Bacillus subtilis YphP, a Prokaryotic Disulfide Isomerase with a CXC Catalytic Motif. *Biochemistry.* 2009; 48:8664–8671. [PubMed: 19653655]
43. Fraser J, Boo I, Pountourios P, Drummer HE. Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry. *J. Biol. Chem.* 2011; 286:31984–31992. [PubMed: 21768113]
44. Wallin M, Ekstrom M, Garoff H. Isomerization of the intersubunit disulphide-bond in Env controls retrovirus fusion. *Embo Journal.* 2004; 23:54–65. [PubMed: 14685283]
45. Li KJ, Zhang SJ, Kronqvist M, Wallin M, Ekstrom M, Derse D, Garoff H. Intersubunit disulfide isomerization controls membrane fusion of human T-cell leukemia virus Env. *J. Virol.* 2008; 82:7135–7143. [PubMed: 18480461]
46. Chernomordik LV, Leikina E, Kozlov MM, Frolov VA, Zimmerberg J. Structural intermediates in influenza haemagglutinin-mediated fusion. *Mol. Membr. Biol.* 1999; 16:33–42. [PubMed: 10332735]

47. Monck JR, Fernandez JM. The fusion pore and mechanisms of biological membrane fusion. *Current Opinion in Cell Biology*. 1996; 8:524–533. [PubMed: 8791451]
48. Li XA, Guo L, Dressman JL, Asmis R, Smart EJ. A novel ligand-independent apoptotic pathway induced by scavenger receptor class B, type I and suppressed by endothelial nitric-oxide synthase and high density lipoprotein. *J. Biol. Chem*. 2005; 280:19087–19096. [PubMed: 15749707]
49. Li XA, Guo L, Asmis R, Nikolova-Karakashian M, Smart EJ. Scavenger receptor BI prevents nitric oxide-induced cytotoxicity and endotoxin-induced death. *Circ.Res*. 2006; 98:E60–E65. [PubMed: 16574909]
50. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Marcel YL, Anderson RGW, Mendelsohn ME, Hobbs HH, Shaul PW. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. *Nat. Med*. 2001; 7:853–857. [PubMed: 11433352]
51. Saddar S, Mineo C, Shaul PW. Signaling by the high-affinity HDL receptor scavenger receptor B type I. *Arterioscler Thromb Vasc Biol*. 2010; 30:144–150. [PubMed: 20089950]
52. Li XA, Titlow WB, Jackson BA, Giltaiy N, Nikolova-Karakashian M, Uittenbogaard A, Smart EJ. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. *J Biol Chem*. 2002; 277:11058–11063. [PubMed: 11792700]
53. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. *Embo J*. 2002; 21:5017–5025. [PubMed: 12356718]
54. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. *J Biol Chem*. 2003; 278:41624–41630. [PubMed: 12913001]
55. Voisset C, Callens N, Blanchard E, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. *J. Biol. Chem*. 2005; 280:7793–7799. [PubMed: 15632171]
56. Dreux M, Dao Thi VL, Fresquet J, Guerin M, Julia Z, Verney G, Durantel D, Zoulim F, Lavillette D, Cosset FL, Bartosch B. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. *PLoS Pathog*. 2009; 5:17.
57. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. *J Virol*. 2010; 84:34–43. [PubMed: 19828610]
58. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A. A genetically humanized mouse model for hepatitis C virus infection. *Nature*. 2011; 474:208–U246. [PubMed: 21654804]
59. Dao Thi VL, Dreux M, Cosset F-L. Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation. *Expert Reviews in Molecular Medicine*. 2011; 13:e13. [PubMed: 21489334]
60. Rice CM. New insights into HCV replication: potential antiviral targets. *Top Antivir Med*. 2011; 19:117–120. [PubMed: 21946389]
61. Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A. A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. *Hepatology*. 2012; 55:364–372. [PubMed: 21953761]

Figure 1.

Identification of the disulfide bond pattern in mouse SR-BI by mass spectrometry. A) Purified SR-BI-t1 was deglycosylated, proteolytically digested (trypsin and GluC) and peptides produced without reduction and alkylation were subjected to LC-MS/MS analysis as described in Experimental Procedures. The MS/MS spectrum of the peptide F³⁰¹TAPDTLFAⁿGSVYPPⁿEGFCp^cR³²⁴ is shown together with the peptide's sequence in which lower case letters denotes amino acids that are modified: deamidated asparagine (n) and oxidized linearized cysteine (c). Both doubly and triply charged forms of the peptide were observed at m/z 1302.0681 and 868.38 respectively, the masses expected for the peptide with a Cys³²¹-Cys³²³ disulfide bond. A) depicts the MS/MS spectrum for the fragmented doubly charged peptide. The amino acid composition of the doubly charged 1302.0681 mass is assigned by the fragmentation pattern where the 'y' and 'b' ion series represent the different cleavage points in the amino acid sequence from the C- or N-termini, respectively. 100% of intensity = 1.2×10^7 . B) Model of mouse SR-BI illustrating the approximate locations of the cysteines in the extracellular loop. Cysteines 251 and 384 are fully reduced (free thiols (-SH), (16)) and disulfide bonds (S-S) link Cys³²¹ to Cys³²³ and Cys²⁸⁰ to Cys³³⁴.

Figure 2.

Effects of CXC (Pro³²²) mutations on ^{125}I -HDL binding (A), $[^3\text{H}]$ cholesteryl ester ($[^3\text{H}]$ CE) uptake from $[^3\text{H}]$ CE-HDL (B) and the lipid transport efficiency (uptake-to-binding ratio) (C). Receptor-specific values were calculated as the differences between the total binding or uptake values (duplicate determinations) and the corresponding nonspecific values measured in the presence of a 40-fold excess of unlabeled HDL (duplicate determinations). Lipid transport efficiency (C) was determined as the ratio of specific $[^3\text{H}]$ CE uptake to specific ^{125}I -HDL binding. Binding and uptake values were normalized to correct for differences in receptor surface expression relative to WT SR-BI based on flow cytometry (WT SR-BI, 1.0; P³²²G, 0.7; P³²²A, 0.7). “EV” (right hand sides of panels A and B) represents the activities of cells transfected with empty vector (EV) as a negative control. D) Representations of the P³²²X mutations introduced in the CPC region of SR-BI (disulfide bonds represented as horizontal dashed lines) and approximate relative ^{125}I -HDL binding values. The P³²²X mutants are shown either as having a CXC intramotif disulfide bond (top) or with side chains of the cysteines indicated by “SH” (bottom), which could represent either a free thiol and/or side chain sulfurs in uncharacterized, aberrant disulfide bonds. Statistical analyses comparing WT SR-BI and mutants were performed using one-way ANOVA with Tukey posttesting (***) $P < 0.0001$.

Figure 3. Effects of XPC (Cys³²¹) or CPX (Cys³²³) mutations on ^{125}I -HDL binding (A), [^3H]cholesteryl ester ([^3H]CE) uptake from [^3H]CE-HDL (B) and the lipid transport efficiency (uptake-to-binding ratio) (C). Receptor-specific ^{125}I -HDL binding (A) and [^3H]CE uptake from [^3H]CE-HDL (B) mediated by WT SR-BI, the indicated C³²¹X or C³²³X mutants (X=G or S) or the empty vector control (EV) in transfected COS cells were measured and results were normalized for relative cell surface expression (WT:1.0; C³²¹G: 0.8; C³²¹S: 0.7; C³²³G: 0.7; C³²³S: 0.6) as described in Figure 2. The residues at positions 321 and 323 are indicated (single letter code) in the grid at the bottom of the figure (empty grid cell represents WT amino acid at that position). D) Representations of the C³²¹X and C³²³X mutations introduced in the CPC region of SR-BI as described in Figure 2 and approximate relative ^{125}I -HDL binding values. Statistical analyses comparing WT SR-BI and mutants were performed using one-way ANOVA with Tukey posttesting (*P<0.01, **P<0.001 and ***P<0.0001).

Figure 4.

Effects of GPG or GXG mutations on ^{125}I -HDL binding (A), $[^3\text{H}]$ cholesteryl ester ($[^3\text{H}]$ CE) uptake from $[^3\text{H}]$ CE-HDL (B) and the lipid transport efficiency (uptake-to-binding ratio) (C). Receptor-specific ^{125}I -HDL binding (A) and $[^3\text{H}]$ CE uptake from $[^3\text{H}]$ CE-HDL (B) mediated by WT SR-BI, the indicated GPG or GXG (X=G or A) double or triple mutants at positions 321-323 or the empty vector control (EV) in transfected COS cells were measured and results were normalized for relative cell surface expression (WT: 1.0; GPG: 0.9; GGG: 1.0; GAG: 1.0) as described in Figure 2. The residues at positions 321-323 are indicated (single letter code) in the grid at the bottom of the figure (empty grid cell represents WT amino acid at that position). D) Representations of the GPG or GXG (X=G or A) double or triple mutations introduced in the CPC region of SR-BI as described in Figure 2 and approximate relative ^{125}I -HDL binding values. Statistical analyses comparing WT SR-BI and mutants were performed using one-way ANOVA with Tukey posttesting and showed no statistically significant differences.

Figure 5.

Effects of mutations of Cys³⁸⁴ on ^{125}I -HDL binding (A), [^3H]cholesteryl ester ([^3H]CE) uptake from [^3H]CE-HDL (B), lipid transport efficiency (uptake-to-binding ratio) (C) and sensitivity to the small molecule inhibitor BLT-1 (D-F). Receptor-specific ^{125}I -HDL binding (A) and [^3H]CE uptake from [^3H]CE-HDL (B) mediated by WT SR-BI or the indicated C³⁸⁴X mutants (X=S, T, L, Y, G, A; one letter amino acid code) in transiently transfected COS cells were measured at 37 °C with a subsaturating concentration of HDL (10 μg of protein/mL) as described in Experimental Procedures. Receptor-specific ^{125}I -HDL binding (A) and [^3H]CE uptake from [^3H]CE-HDL (B) mediated by WT SR-BI, the indicated P³²²X mutants (X=G or A) or the empty vector control (EV) in transfected COS cells were measured and results were normalized for relative cell surface expression (WT SR-BI, 1.0; C³⁸⁴S, 0.9; C³⁸⁴T, 1.0; C³⁸⁴L, 1.0; C³⁸⁴Y, 1.0; C³⁸⁴G, 0.9; and C³⁸⁴A, 0.9) as described in Figure 2. D) Structure of BLT-1 with its thiosemicarbazone moiety shaded. ^{125}I -HDL binding (E) and [^3H]CE uptake from [^3H]CE-HDL (F) activities of WT SR-BI and C³⁸⁴X mutants were determined in the presence or absence of an excess (1 μM) of BLT-1. Values are expressed as the percentage change in receptor activity induced by BLT-1 and are calculated as the difference between activities in the presence and absence of BLT-1, divided by the activity in the absence of BLT-1. The activities without BLT-1 in the same experiment are shown in panels A (binding) and B (uptake). Negative values in panels E and F represent loss of activity in the presence of BLT-1. Statistical analyses comparing WT SR-BI and mutants were performed using one-way ANOVA with Tukey posttesting (* $P < 0.01$, ** $P < 0.001$ and *** $P < 0.0001$).

Figure 6.

Alignment of extracellular cysteine residues in mammalian CD36 superfamily members: SR-BI, CD36 and LIMPII. The approximate relative locations of the six extracellular cysteines in both SR-BI and CD36, and five extracellular cysteines in LIMPII are illustrated (positions in the amino acid sequences are shown). Dashes indicate the absence of cysteines when compared to the presence of cysteines at equivalent locations in other family members (e.g., there are no equivalent cysteines in CD36 or LIMPII to Cys³⁸⁴ in SR-BI). The disulfide bonds reported for mouse SR-BI (this study) and bovine CD36 (35) are shown as lines connecting the sulfur atoms in the side chains of the cysteines. The dotted lines represent disulfide bonds that are in equivalent positions in the SR-BI and CD36 sequences. The disulfide bonding pattern of LIMPII has not yet been reported.